Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

 
Press Releases
  Date Title View
Sep 20, 2016
Mateon Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a clinical-stage biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced it will present an overview of the company at the Ladenburg Thalmann 2016 Healthcare Conference ...

Sep 7, 2016
Mateon Therapeutics to Present at the 18th Annual Rodman and Renshaw Global Investment Conference in New York on September 12, 2016

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a clinical-stage biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investmen...

Aug 3, 2016
Mateon Provides Corporate Update and Reports Second Quarter 2016 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for the second quarter of 2016. Recent Corporate ...

Jul 21, 2016
Mateon Announces Enrollment of First Patient in Phase 2 Portion of PAZOFOS Study in Recurrent Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., July 21, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the first patient has been enrolled into the Phase 2 portion of the PAZOFOS Study. The PAZOFOS Study...

Jun 23, 2016
Mateon Announces Initiation of FOCUS Study in Platinum-Resistant Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., June 23, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that it has enrolled the first patient into its FOCUS Study, a phase 2/3 clinical trial of CA4P for the t...

Jun 20, 2016
Mateon Therapeutics to Present New Improved Survival Outcomes for CA4P in Recurrent Ovarian Cancer at June 27 Investor Event

Updated data shows improvement in overall survival of 3.2 months for all CA4P-treated patients Improvement in overall survival is 5.6 months for CA4P-treated patients with measurable disease SOUTH SAN FRANCISCO, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascula...

Jun 17, 2016
OXiGENE Announces Name Change to Mateon Therapeutics

SOUTH SAN FRANCISCO, Calif., June 17, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for orphan oncology indications, today announced that it has changed its name to Mateon Therapeutics, Inc., effective immediately. On the NASDAQ Capital Market, the name change will b...

Jun 10, 2016
OXiGENE Receives U.S. Orphan Drug Designation for CA4P to Treat Glioma

SOUTH SAN FRANCISCO, Calif., June 10, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CA4P for the treatment of gli...

May 24, 2016
OXiGENE Announces Results of Phase 2 Study of CA4P in Recurrent Ovarian Cancer Published in Journal of Clinical Oncology

Study met primary endpoint of improvement in progression free survival Preliminary data show improvement in overall survival of 2.6 months SOUTH SAN FRANCISCO, Calif., May 24, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology ind...

May 9, 2016
OXiGENE Reports First Quarter 2016 Financial Results

SOUTH SAN FRANCISCO, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today reported financial results for the first quarter of 2016. For the three months ended March 31, 2016, OXiGENE reported a n...

1
...
NextLast
= add release to Briefcase